Evidence map›Paper›PMID 32047579›Full record

ArticleOxidative medicine and cellular longevity2020

Shyh-Horng Lin, Ming-Han Li, Kai-An Chuang, Ni-Hsuan Lin, Chih-Hsuan Chang, Hsin-Chieh Wu, Ya-Hsuan Chao, Chi-Chien Lin, I-Hong Pan, Ming-Der Perng and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Complementary and Alternative Therapies in Oncology.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Shyh-Horng LinBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0001-5290-9265
Ming-Han LiBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.
Kai-An ChuangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0002-0870-4198
Ni-Hsuan LinInstitute of Molecular Medicine, College of Life Sciences, National Tsing Hua University, 101 Kuang Fu 2 Road, Hsinchu 30013, Taiwan.ORCID https://orcid.org/0000-0003-4524-3615
Chih-Hsuan ChangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0002-1827-6940
Hsin-Chieh WuBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0002-2000-4127
Ya-Hsuan ChaoInstitute of Biomedical Science, National Chung-Hsing University, 145 Xingda Road, Taichung 40227, Taiwan.ORCID https://orcid.org/0000-0001-8283-6589
Chi-Chien LinInstitute of Biomedical Science, National Chung-Hsing University, 145 Xingda Road, Taichung 40227, Taiwan.ORCID https://orcid.org/0000-0002-1464-0231
I-Hong PanBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0002-9959-6224
Ming-Der PerngInstitute of Molecular Medicine, College of Life Sciences, National Tsing Hua University, 101 Kuang Fu 2 Road, Hsinchu 30013, Taiwan.ORCID https://orcid.org/0000-0002-1884-3714
Shu-Fang WenBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2 Road, Hsinchu 30011, Taiwan.ORCID https://orcid.org/0000-0001-9066-553X
ITRI International · USNational Chung Hsing University · TWNational Tsing Hua University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin chemotherapy causes myelosuppression and often limits treatment duration and dose escalation in patients. Novel approaches to circumvent or lessen myelotoxicity may improve clinical outcome and quality of life in these patients.

Indexed as

Antineoplastic AgentsBone Marrow CellsCD11b AntigenChlorellaCisplatinDrug-Related Side Effects and Adverse ReactionsGranulocyte-Macrophage Colony-Stimulating FactorHL-60 CellsHumansImmunomodulationImmunosuppression TherapyMitochondriaMyeloid CellsPlant ExtractsAntineoplastic AgentsCD11b AntigenCisplatinGranulocyte-Macrophage Colony-Stimulating FactorPlant Extracts

Identifiers

PMID32047579
PMCPMC7003270
OpenAlexW3002233311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.